To examine whether the prophylactic antianginal agent perhexiline potentiates platelet responsiveness to nitric oxide (NO) in patients with stable angina pectoris (SAP) and acute coronary syndromes (ACS: unstable angina pectoris or non-Q-wave myocardial infarction).
Introduction
Nitric oxide (NO) is a physiologically important modulator of both vasomotor tone and platelet aggregability.
Experiments by Folts and co-workers [1] in a canine model of acute coronary syndrome (ACS) have demonstrated a critical role for NO in preventing coronary occlusion via inhibition of platelet aggregation. We have shown that platelet responsiveness to antiaggregating effects of NO donors is reduced in patients with ACS relative to that from normal subjects [2] . Furthermore, recent investigations have indicated that both platelets [3] and coronary arteries [4] from patients with stable angina pectoris (SAP) are hypo-responsive to the antiaggregatory and coronary vasodilator effects of NO. Evidence is accumulating to suggest that resistance to these NO effects may also be associated with a number of coronary risk factors, such as hypertension [5] and hyperlipidaemia [6] . Furthermore, in both the human brachial [7] and coronary [4] arteries, vasomotor resistance to NO correlates with conventional measures of 'endothelial dysfunction'.
Our recent studies [3] suggest that inactivation of soluble guanylyl cyclase and clearance of NO by O 2 are factors contributing to platelet hypo-responsiveness to NO donors such as nitroglycerin and sodium nitroprusside (SNP) in patients with SAP. Comparison with patients with unstable angina pectoris revealed even more marked hypo-responsiveness to SNP [2] . Multivariate analysis of potential correlates of the presence/ absence of platelet resistance to NO suggested that while most forms of pharmacotherapy had little impact, therapy with the prophylactic antianginal agent perhexiline was associated with better responsiveness to NO [2] . Previous clinical studies with perhexiline have demonstrated markedly beneficial effects of the drug on symptomatic status in patients with SAP [8] [9] [10] [11] , even when perhexiline is utilized as incremental therapy to conventional prophylactic antianginal agents. This may reflect improvement of myocardial energetic status [12] , since perhexiline increases efficiency of myocardial oxygen utilization, via inhibition of carnitine palmitoyltransferase-1, which controls access of long-chain fatty acids to mitochondrial -oxidation [12] . While there is evidence to suggest that perhexiline may also improve symptoms in patients with unstable angina pectoris [13] , few clinical studies have addressed this area.
The principal objective of the current study was to examine the effect of short-term therapy with perhexiline on platelet responsiveness to the NO donor SNP and to evaluate potential correlates with changes in anginal frequency in perhexiline-treated patients with ACS, consisting of unstable angina pectoris or non-Q-wave myocardial infarction. Additional studies were performed to determine whether similar effects occur in SAP patients. We also investigated potential biochemical mechanism(s) of the observed effects of perhexiline.
Methods

Patients
Studies were performed on the following groups of patients:
(1) Patients with SAP awaiting initiation of perhexiline therapy for angina pectoris refractory to conventional pharmacotherapy [8] . Indications for treatment with perhexiline were the presence of Canadian Class III or IV symptoms in spite of maximally tolerated therapy with other prophylactic antianginal agents (nitrates, -adrenoceptor antagonists and/or calcium antagonists), together with unsuitability for coronary revascularization. The presence of preexistent hepatic dysfunction and/or concomitant therapy with amiodarone were contraindications to treatment with perhexiline. (2) Patients with ACS (unstable angina pectoris or non-Q-wave myocardial infarction) admitted to the Coronary Care Unit less than 24 h prior to onset of investigation. Indication for initiation of perhexiline therapy was occurrence of symptomatic myocardial ischaemia at rest despite pharmacotherapy including aspirin, intravenous heparin, intravenously infused nitroglycerin, plus orally administered prophylactic antianginal agents. Patients receiving glycoprotein II b /III a inhibitors or ADP antagonists, or who were scheduled for coronary revascularization within 72 h of initiation of perhexiline therapy were excluded from the study.
Quantification of anginal episodes in patients with SAP was via completion of daily diaries, in patients with ACS episodes of symptomatic ischaemia were recorded, and effect of perhexiline calculated on the basis of total episodes of angina 24-72 h post initiation of treatment. The study was approved by the institution's Ethics of Research Committee; written informed consent was obtained prior to study entry.
Treatment regimen
A group of 12 patients with ACS received no perhexiline for the first 72 h of admission; assessment of platelet responses to SNP at the beginning and end of this period was used to investigate whether these responses varied with time post admission. In patients with ACS starting treatment with perhexiline, initial dosage was 200 mg twice daily for 3 days to achieve therapeutic plasma concentrations of perhexiline (0·15 to 0·60 g . ml 1 ) within 72 h [13, 14] . In patients with SAP, initial dosage was 100 mg twice daily; therapeutic drug concentrations were attained within 1 week [14] . In view of the potential hypoglycaemic effects of perhexiline in diabetics [9, 13] , dosage of sulfonylureas or insulin was to be reduced after initiation of treatment with perhexiline wherever necessary. In all other respects, prior treatment was kept constant following initiation of perhexiline therapy.
All patients with ACS remained in the Coronary Care Unit for at least 72 h following initiation of the study. Numbers of episodes of angina pectoris were recorded daily. Blood glucose levels were monitored closely in diabetic subjects, while plasma perhexiline levels were determined after 72 h of therapy.
Blood sampling and preparation of platelets and neutrophils
Blood samples were drawn by venesection from an antecubital vein. Blood was collected into plastic tubes containing 1:10 volume of acid citrate (two parts of 0·1 mol . l 1 citric acid to three parts of 0·1 mol . l 1 trisodium citrate) for platelet aggregation studies [3] , or 24 mmol . l 1 EDTA for neutrophil preparation. Blood was centrifuged at 250 g for 10 min at room temperature to obtain platelet-rich plasma. Platelet-poor plasma was prepared by further centrifugation of the remaining blood at 2500 g for 20 min. Platelet counts were performed on the STKS Coulter Counter (Coulter Electronics Inc) and the platelet-rich plasma was adjusted with platelet-poor plasma to a constant count of 250 000/ l. For neutrophil preparation, blood samples were centrifuged at 120 g for 10 min, and plasma was replaced by an equal volume of Hanks' balanced salt solution (HBSS) pH 7·4. Neutrophils were isolated using a Ficoll-Hypaque gradient. Following centrifugation at 550 g for 30 min, the lower layer containing neutrophils and red blood cells was collected. Following lysis of the red blood cells and washing to remove the lysis buffer (ammonium chloride 155 mmol . l 1 , EDTA 100 mol . l 1 , NaHCO 3 10 mmol . l 1 ), the neutrophils were pelleted (550 g, 10 min) and resuspended in HBSS pH 7·4 at 1·7 10 6 cells per ml.
Platelet aggregation studies
All aggregation studies were performed utilizing a dualchannel impedance lumi-aggregometer (Model 560, Chrono-Log, Havertown, Pennsylvania, U.S.A.) as previously described [3] . In all cases, aggregation was induced with adenosine 5 -diphosphate (ADP, final concentration of 1 mol . l 1 ), and responses were recorded for electrical impedance, in ohms. SNP (final concentration of 10 mol . l 1 ) was added to samples 1 min before ADP. Inhibition of aggregation by SNP was evaluated as percentage of maximal aggregation in the absence of SNP.
Intraplatelet cGMP determination
Platelet-rich plasma (0·5 ml) was incubated at 37 C with SNP (10 mol . l 1 ) for 1 min. Intraplatelet cGMP content was assayed as described previously [3] . Briefly, after incubation plasma was filtered through GF/C Glass Microfibre Filters (Whatman, U.K.) for harvesting the platelets. Filters with absorbed platelets were rinsed with physiological saline and placed into 0·5 ml of 4 mmol l 1 EDTA for further extraction of cGMP in a boiling water bath for 5 min. After centrifugation of samples at 3000 g for 10 min, cGMP concentration in supernatant was estimated using 'cGMP [125] assay system' (Amersham). Results were expressed as pmol cGMP/10 9 platelets.
Chemiluminescence assay of O 2
Whole blood Detection of O 2 in whole blood was performed utilizing lucigenin-derived chemiluminescence as described previously [3] . Blood samples were diluted twofold with normal saline (final volume 1 ml) and prewarmed for 5 min at 37 C before the addition of lucigenin. Initial studies were performed utilizing 125 mol . l 1 lucigenin [15] . In view of emerging data suggesting that this high concentration of lucigenin might induce increased redox cycling, additional validation experiments were performed with 12·5 mol . l 1 lucigenin [16] . Chemiluminescence was monitored using a photoluminometer component of a dual-channel lumi-aggregometer (Model 560, Chrono-Log, Havertown, Pennsylvania, U.S.A.). Intensity of chemiluminescence was expressed in millivolts (mV) . 
Neutrophils
Data analysis
Changes in extent of aggregation and SNP responsiveness produced by perhexiline therapy were examined using paired t-test. Comparisons between subgroups were made using non-paired t-test. The relationship between changes in SNP responsiveness, extent of ADPinduced aggregation and plasma perhexiline concentration was examined using linear regression. In patients with ACS, correlations were sought between changes in platelet responses to SNP and resolution/non-resolution of symptomatic myocardial ischaemia. Data for inhibition of O 2 release from neutrophils in vitro were analysed via two-way analysis of variance (ANOVA). Statistically significant difference was limited to P<0·05. Results are expressed as mean standard error of the mean. Table 1 summarizes the baseline clinical and demographic characteristics of patients according to the diagnosis of SAP or ACS. As stated, in all 30 patients with SAP perhexiline therapy had been initiated because of severe angina despite maximally tolerated therapy, with unsuitable coronary anatomy for surgical revascularization or coronary angioplasty. All ACS patients (n=62) had been admitted to the Coronary Care Unit with prolonged ischaemic chest pain occurring at rest; 36 (42%) patients had enzyme criteria for non-Q-wave myocardial infarction. Clinical or demographic characteristics did not differ significantly between those patients receiving (n=50) and not receiving (n=12) perhexiline during the first 3 days of hospital admission.
Results
Patient characteristics
Clinical effects of perhexiline therapy.
Patients with stable angina pectoris The effect of short-term (8·0 0·6 days) perhexiline therapy was examined in patients with SAP. Prior to commencement of perhexiline therapy anginal frequency in these patients was 6·7 0·9 episodes per day, while after short-term therapy anginal frequency had decreased to 1·0 0·3 episodes per day (P<0·001, Fig. 1 ). Plasma perhexiline concentration in this cohort of patients was 0·68 0·15 g . ml 1 . Six patients developed transient mild nausea and dizziness, associated with elevation of perhexiline levels beyond the therapeutic range (i.e. >0·60 g . ml 1 ) .
Patients with acute coronary syndromes
Thirty-nine of the 50 ACS patients treated with perhexiline experienced no further episodes of angina within the period of 24 to 72 h after commencement of therapy. The remaining 11 patients continued to experience anginal pain, although none required emergency coronary revascularization. No patient sustained new myocardial infarction after commencement of perhexiline therapy; no patients died in hospital. Seven patients developed nausea and/or dizziness, but in no case were these symptoms sufficiently severe to cause interruption or cessation of perhexiline therapy. None of the 17 diabetic patients developed symptomatic hypoglycaemia. In patients with ACS in whom perhexiline therapy was initiated (n=50), plasma perhexiline concentrations after 3 days of therapy were 0·61 0·08 g . ml 1 . Consistent with our previous observations [13] , nausea and dizziness occurred only in the presence of plasma perhexiline concentrations greater than 0·60 g . ml 1 . 
Effects of perhexiline on ex vivo platelet aggregation
Patients with stable angina pectoris One week after commencement of perhexiline therapy there was no significant difference in the extent of ADP-induced aggregation (10·8 0·9 ohms) when compared to baseline (11·1 0·9 ohms). After 4 weeks of perhexiline therapy (n=14), the extent of platelet aggregation was also not significantly different from baseline (9·8 1·2 vs 11·4 1·4 ohms). Therefore perhexiline did not appear to have a 'direct' antiaggregatory effect when assessed ex vivo in this group of patients. However, there was a significant increase from baseline values in SNP responses after perhexiline therapy (35 5 vs 52 4% inhibition of aggregation, P<0·001, Fig. 2 ). There was no further increase in the extent of platelet responsiveness to SNP between 1-2 weeks and 4 weeks of treatment.
Patients with acute coronary syndromes
In those patients treated with perhexiline for 3 days, ADP-induced aggregation remained unchanged (12·5 0·8 vs 12·9 0·8 ohms). This result is consistent with that of patients with SAP. However, SNP response increased from 29 2% inhibition of aggregation at baseline to 43 4% inhibition of aggregation (P<0·001, Fig. 3(a) ). In 12 additional patients, aggregation experiments were also performed in platelet-rich plasma to minimize the possible influence of neutrophil derived O 2 on platelet effects of NO. After 3 days treatment with perhexiline, platelet responsiveness to SNP increased from 20 5 to 42 7% inhibition of aggregation (P<0·01). The potential relationship in individual patients between resolution/continuation of angina and changes in SNP response was also examined. In patients with continued angina, there was no increase in platelet responsiveness to SNP (35 6 vs 26 6% inhibition of aggregation, before and after perhexiline), whereas resolution of angina was associated with an increase in SNP response from 26 3 to 48 4% inhibition of aggregation (P<0·001, Fig. 3(b) ). Thus significantly greater (P<0·01) increments in SNP responsiveness occurred in patients with resolution than with nonresolution of ischaemia.
In the patients in whom perhexiline therapy was not initiated (n=12), baseline SNP responsiveness was 33 4% inhibition of aggregation. This value did not significantly differ from the baseline value for those patients treated with perhexiline (29 2 vs 33 4% inhibition of aggregation, respectively). However, in contrast to those patients receiving perhexiline, 3 days of conventional therapy did not affect the SNP response (33 5 vs 33 4% inhibition of aggregation, P=0·82). These data therefore suggest that perhexiline therapy rather than the efflux of time and symptomatic status is responsible for the increase in SNP response. Within this group of patients we also examined extent of ADPinduced aggregation. No significant reduction in extent of aggregation was observed over the 3 days follow-up period.
Mechanisms of perhexiline effects
In vitro platelet aggregation Effects of perhexiline on platelet aggregation and platelet responsiveness to SNP in vitro were assessed in blood samples obtained from 11 patients with SAP not receiving perhexiline. In accordance with previous findings [17] , preincubation of blood samples for 5 min with perhexiline in concentrations of 1 and 10 mol . l 1 produced a small decrease in ADP-induced platelet aggregation (3 2 and 19 5% inhibition of aggregation, respectively), while SNP (10 mol . l 1 ) alone produced 30 7% inhibition of aggregation. Incremental addition of perhexiline (1 and 10 mol . l 1 ) did not alter the extent of this inhibition. Thus, there was no direct effect of perhexiline on platelet responsiveness to NO donor.
Nitric oxide
Because of the involvement of the cGMP-system in the antiaggregatory effects of NO, we investigated the possible influence of the perhexiline treatment on intraplatelet cGMP accumulation in response to a NO donor. A decreased NO-sensitivity of platelets from patients with ACS and SAP may reflect either impaired platelet guanylyl cyclase or reduced availability of NO for activation of guanylyl cyclase because of a clearance of NO by O 2 in blood [3] . Improvement in platelet NO responsiveness can, therefore, reflect interference of perhexiline treatment with these entities. In further experiments we examined the effects of perhexiline on O 2 ex vivo and in vitro, utilizing both whole blood samples and neutrophil preparations, and also assessed intraplatelet cGMP accumulation in response to SNP. 
Whole blood superoxide
In blood samples from ACS patients scheduled to begin treatment with perhexiline, O 2 content was directly measured via lucigenin-derived chemiluminescence, utilizing two concentrations of lucigenin, 12·5 and 125 mol . l 1 . After perhexiline therapy, there was no significant difference in O 2 when compared to baseline values: 39 6 vs 37 5 mV with 12·5 mol . l 1 lucigenin (n=10) and 136 41 vs 107 27 mV with 125 mol . l 1 lucigenin (n=11). Superoxide content was also examined in ACS patients not receiving perhexiline; after 3 days of conventional therapy the O 2 content was not significantly different from baseline.
Neutrophil superoxide
Preincubation of isolated neutrophils from normal volunteers (n=6) with perhexiline lactate (2 mol . l 1 ) inhibited fMLP-stimulated O 2 production, with the inhibitory effect increasing with time of preincubation up to 30 min (Fig. 4) . Preincubation for 15 min inhibited O 2 production by 28 13% (P<0·05 vs control), while 30 and 60 min preincubation inhibited O 2 production by 68 5 and 65 8%, respectively (P<0·01 vs control). This effect of perhexiline was not attributable to a scavenging effect on O 2 since the presence of 2 mol . l 1 perhexiline lactate did not reduce the chemiluminescence signal generated by in vitro production of O 2 from hypoxanthine by isolated xanthine oxidase (counts: sodium lactate 2 mol . l 1 , 43 600 2800; perhexiline lactate 2 mol . l 1 , 39 600 3200; n=6) .
Intraplatelet cGMP
In samples from nine patients with ACS starting treatment with perhexiline, we assayed intraplatelet cGMP content before and after incubation of platelet-rich plasma with 10 mol . l 1 SNP. Basal cGMP concentrations did not change after 3 days of therapy with perhexiline (0·58 0·06 vs 0·63 0·11 pmol cGMP/10 platelets). There was, however, a significant increase in platelet responsiveness to cGMP-elevating effects of SNP after treatment with perhexiline, from 149 7 to 191 14% of control (P=0·03). There was a strong correlation between the increases in cGMP-elevating effects of SNP and its antiaggregatory effects in WB (r=0·87, P<0·01; Fig. 5 ).
Discussion
Previous studies [8] [9] [10] [11] 18, 19] have demonstrated that perhexiline, a carnitine palmitoyltansferase-1 (CPT-1) inhibitor and prophylactic antianginal agent markedly reduces symptomatic severity in patients with SAP; these observations are supported by the current study. Specifically, perhexiline reduced anginal frequency by 85% in SAP patients. Similarly, rapid loading with perhexiline in patients with ACS also was associated with a 78% reduction in proportion of symptomatic patients within 3 days. As the current study did not include a randomized control group, these data can be regarded purely as being consistent with previous results concerning the considerable antiischaemic efficacy of perhexiline. The novel aspect of the current study related to the associated finding of changes in platelet responsiveness to SNP. Our previous studies in a large cohort of patients with angina pectoris suggested that the phenomenon of platelet resistance to the antiaggregatory effects of NO occurs in the majority of patients with SAP [3] and is somewhat more pronounced in patients with ACS [2] . In the latter study multivariate analysis revealed that therapy with perhexiline is associated with increased platelet responsiveness to NO [2] . The current study has prospectively tested this association. We investigated relationships between perhexiline effects at the level of platelet aggregation and changes in clinical status, and explored possible biochemical mechanism(s) underlying these changes. The central finding of the current study was that perhexiline therapy, even for the short period of time associated with 'loading' of the drug [14] , induces a marked potentiation of platelet sensitivity to NO in both SAP and ACS patients (Figs 2 and 3 ). This potentiation cannot be ascribed purely to the efflux of time in patients: in patients not treated with perhexiline, there was no change in platelet responsiveness over the same time period.
As patients improving clinically with perhexiline therapy had progressive withdrawal of intravenous nitrate therapy, it is likely that any degree of nitrate tolerance would have diminished in this group. Nevertheless, platelet responsiveness to SNP reflects 'direct' tissue responsiveness to NO; there is no cross-tolerance between nitroglycerin and SNP either in platelets [20] or in human vessels [21] . Thus the potentiation of SNP responsiveness by perhexiline reflects alterations in NO kinetics and/or tissue responsiveness to NO, without any implication of changes in nitrate bioconversion kinetics [21] . A major purpose of the study was to explore the therapeutic implications of perhexiline-induced changes in platelet responsiveness to SNP. As summarized in the data shown in Fig. 3 , there was a direct relationship between extent of increase in platelet response to SNP in the first 3 days of therapy and the probability of resolution of ischaemic symptoms within 3 days in the ACS group. The change in SNP response proved to be a stronger predictor of short-term symptomatic outcome than simultaneous plasma perhexiline concentrations. The current findings therefore imply that therapeutic improvement in platelet responsiveness to NO may be an important determinant of outcome in patients with ACS. 
Mechanism of perhexiline effect
The potentiating effects of perhexiline on SNP-induced inhibition of platelet aggregation did not occur in acute experiments in vitro, although perhexiline alone in concentrations corresponding to the therapeutic range for the drug (0·5-2·0 mol . l 1 ) does exert weak antiaggregatory effects [17] . The current result therefore implies a slowly developing effect of perhexiline in vivo on the biochemical determinants of platelet responsiveness to NO.
We have previously demonstrated [3] that platelet resistance to NO can be ascribed to a combination of increased clearance of NO by O 2 and to (possibly reversible) inactivation of platelet soluble guanylyl cyclase. The first experiments performed, therefore, evaluated perhexiline effects on determinants of O 2 release. Whole blood O 2 concentrations did not change significantly following 3 days' treatment with perhexiline, suggesting that perhexiline did not act via changes in O 2 kinetics. However, perhexiline was found to inhibit fMLP-induced O 2 release from neutrophils in vitro (Fig. 4) . Since this effect occurred with concentrations of perhexiline within the therapeutic range for the drug [8, 9, 14] , the possibility that perhexilineinduced inhibition of 'neutrophil-burst'-induced release of O 2 might be therapeutically important cannot be excluded. Probably of greater clinical relevance was the effect of perhexiline therapy on intraplatelet cGMP formation in response to SNP. Perhexiline did not affect intraplatelet cGMP level in either acute experiments in vitro [17] , or ex vivo, after perhexiline treatment (current study). Nonetheless, the potentiation of SNP effect occurred both in whole blood and in platelet-rich plasma (despite the low potential for O 2 release in platelet-rich plasma). This suggests that the major mechanism whereby perhexiline improves SNP response is via restoring to normal platelet soluble guanylyl cyclase responsiveness to NO. The additional finding of a significant correlation between extent of perhexilineinduced potentiation of cGMP-elevating and antiaggregating effects of SNP (Fig. 5) suggests a common mechanism for both these phenomena. As perhexiline [22] , like other carnitine palmitoyltransferase-1 inhibitors [23] , act as an insulin-sensitizing agent, it is possible that a component of the perhexiline effect is related to an insulin-mediated increase in platelet responsiveness to NO [24] .
Limitations of the study
A number of important issues have not been addressed in the current study. From a purely clinical point of view, none of the ACS patients had been treated either with enoxaparine or with glycoprotein II b /III a antagonists, which may exert incremental antiischaemic effects in such patients [25, 26] , it is therefore uncertain whether the therapeutic impact of perhexiline would have been as marked in the presence of these agents. Furthermore, the study was not designed to quantitate precisely the extent of antiischaemic effect of perhexiline, but rather to investigate whether perhexiline effects on platelet NO responsiveness might be correlates of clinical outcome. Nevertheless, the profound antiischaemic effects of perhexiline have been documented in numerous previous studies, both with monotherapy [10] and in combination with other agents [8, 11, 14] .
Conclusions
A number of recent studies have indicated that vascular hypo-responsiveness to NO may represent a critical component of 'endothelial dysfunction', which carries adverse prognostic implications [4] ; our previous studies have demonstrated similar anomalies in platelets from patients with SAP [3] and particularly ACS [2] . The major finding of the current investigation, that perhexiline tends to normalize platelet responsiveness to NO in both these groups of patients, represents the first therapeutic advance as regards this platelet dysfunction. The clinical importance of this effect is evident from the fact that increment in responsiveness to NO in individual patients was directly associated with resolution of ischaemic symptoms. Normalization of platelet responsiveness to NO thus may represent a novel strategy for the management of acute myocardial ischaemia.
